Recommendation of Final Dividend of Rs. 9.30 (930%) per share of face value Re. 1 each for financial year 2025-26

Corporate Actions View source PDF Explain this filing

JBCHEPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.3%Reaction day

₹2212.70

prior close

₹2152.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-3.0%-0.3% vs market

Pharmaceuticals peers, median of 164sector-2.4%-0.9% vs sector

On the reaction day the stock moved 0.3 pts less than Nifty Smallcap 250 and 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

-0.0

15m

-0.2

30m

+0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.3-3.0-0.3-2.4-0.9

Next day

-4.8-2.7-2.1-2.4-2.4

-3.5-2.7-0.8-1.0-2.5

-3.7-3.1-0.6-1.9-1.8

-4.1-4.5+0.5-2.5-1.5

-2.1-3.4+1.3-2.0-0.1

-1.4-2.6+1.2-0.5-0.9

15d

-3.3-1.7-1.5-1.1-2.2

+2.0-1.0+3.1-0.0+2.1

+11.0+5.3+5.7+5.1+6.0

—+6.3—+7.7—

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The Board of Directors of JB Chemicals & Pharmaceuticals Ltd has recommended a final dividend of Rs. 9.30 per equity share (930% on face value of Re. 1) for FY 2025-26. This dividend is subject to approval by shareholders at the ensuing Annual General Meeting. If approved, the dividend will be remitted within 30 days of declaration. The Board meeting was held on May 11, 2026, and lasted from 6:15 PM to 6:56 PM.

Likely market impact

The 930% dividend payout signals strong cash generation and financial health. This is a positive signal for shareholders expecting returns, though the actual impact on stock price will depend on market expectations and the stock's prevailing price.